在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human pulmonary activation regulated chemokine,PARC ELISA Kit

  • 中文名稱:
    人肺部活化調節趨化因子(PARC/CCL18)酶聯免疫試劑盒
  • 貨號:
    CSB-E09941h
  • 規格:
    96T/48T
  • 價格:
    ¥3200/¥2500
  • 其他:

產品詳情

  • 產品描述:
    人肺部活化調節趨化因子(PARC/CCL18)酶聯免疫試劑盒(CSB-E09941h)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織培養上清液、組織勻漿樣本中的CCL18含量。CCL18是一種重要靶點。它屬于趨化因子家族,在免疫調節等生理過程中發揮作用。研究發現其在腫瘤微環境、免疫性疾病中表達異常。機制上,它能招募免疫細胞、影響細胞遷移和活化,為相關疾病的治療和研究提供了方向。試劑盒檢測范圍為31.25 pg/ml-2000 pg/ml,靈敏度為7.81 pg/ml。適用于體外實驗中探究肺部疾病模型、免疫調控機制、藥物干預效果等科研場景本品僅用于科研,不用于臨床診斷,產品具體參數及操作步驟詳見產品說明書。
  • 別名:
    Alternative macrophage activation associated CC chemokine 1 ELISA Kit; Alternative macrophage activation-associated CC chemokine 1 ELISA Kit; AMAC-1 ELISA Kit; AMAC1 ELISA Kit; CC chemokine PARC ELISA Kit; CCL18 ELISA Kit; CCL18(4-69) ELISA Kit; CCL18_HUMAN ELISA Kit; CKb7 ELISA Kit; DC-CK1 ELISA Kit; DCCK1 ELISA Kit; DCCK1 ELISA Kit; Dendritic cell chemokine 1 ELISA Kit; Macrophage inflammatory protein 4 ELISA Kit; MIP-4 ELISA Kit; MIP4 ELISA Kit; PARC ELISA Kit; Pulmonary and activation regulated chemokine ELISA Kit; Pulmonary and activation-regulated chemokine ELISA Kit; SCYA18 ELISA Kit; Small inducible cytokine A18 ELISA Kit; Small inducible cytokine A18 ELISA Kit; Small-inducible cytokine A18 ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, cell culture supernates, tissue homogenates
  • 檢測范圍:
    31.25 pg/ml-2000 pg/ml
  • 靈敏度:
    7.81 pg/ml
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Immunology
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

     

    Intra-Assay Precision

    Inter-Assay Precision

    Sample

    1

    2

    3

    1

    2

    3

    n

    20

    20

    20

    20

    20

    20

    Mean(ng/ml)

    244.406

    249.006

    237.517

    236.211

    239.732

    235.807

    SD

    0.045

    0.055

    0.052

    0.066

    0.072

    0.078

    CV(%)

    4.011

    4.685

    4.510

    5.820

    6.081

    6.915

  • 線性度:

    To assess the linearity of the assay, samples were spiked with high concentrations of human PARC/CCL18 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

     

    Sample

    Serum(n=4)

    1:100

    Average %

    91

    Range %

    87-94

    1:200

    Average %

    97

    Range %

    95-103

    1:400

    Average %

    98

    Range %

    95-102

    1:800

    Average %

    93

    Range %

    91-98

  • 回收率:

    The recovery of human PARC/CCL18 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    91

    87-94

    EDTA plasma (n=4)

    98

    95-102

  • 標準曲線:

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    pg/ml

    OD1

    OD2

    Average

    Corrected

    2000

    2.466

    2.585

    2.526

    2.394

    1000

    1.991

    1.944

    1.968

    1.836

    500

    1.482

    1.567

    1.525

    1.393

    250

    1.213

    1.130

    1.172

    1.040

    125

    0.832

    0.900

    0.866

    0.734

    62.5

    0.477

    0.450

    0.464

    0.332

    31.25

    0.244

    0.251

    0.248

    0.116

    0

    0.129

    0.135

    0.132

     

  • 數據處理:
  • 貨期:
    3-5 working days

產品評價

靶點詳情

  • 最新研究進展:
    CCL18是一種趨化因子,在多種疾病的發病和發展中起著重要作用,如癌癥、肝病和心臟病等。最近的研究表明,CCL18在慢性阻塞性肺疾病(COPD)患者中的水平與氣流受限程度和炎癥程度相關。這些發現表明CCL18可能是COPD的潛在生物標志物,并提供了CCL18可能參與COPD發病機制的新證據。
  • 功能:
    Chemotactic factor that attracts lymphocytes but not monocytes or granulocytes. May be involved in B-cell migration into B-cell follicles in lymph nodes. Attracts naive T-lymphocytes toward dendritic cells and activated macrophages in lymph nodes, has chemotactic activity for naive T-cells, CD4+ and CD8+ T-cells and thus may play a role in both humoral and cell-mediated immunity responses.
  • 基因功能參考文獻:
    1. miR-128 interacts with CCL18 3'UTR, reducing its expression in malignant melanoma. PMID: 30025750
    2. AMAP1 mediated CCL18-induce activation of NF-kappaB and promoted breast cancer metastasis. PMID: 28834540
    3. results of the study indicate that there could be a relationship between the expression of CCL-18 in nasal turbinate mucosa and the severity of allergic rhinitis PMID: 30102123
    4. chemokine CCL18 can be a mediator of peritoneal membrane failure associated with peritonitis episodes as well as providing a new potential therapeutic target. PMID: 29850544
    5. CCL18 was up-regulated in diffuse large B cell lymphoma and related to poor prognosis PMID: 29504526
    6. Serum C-C motif chemokine ligand 18 (CCL18) was elevated in patients with epithelial ovarian cancer (EOC) and could serve as a new tumor biomarker, which also predicted a poor survival of the patient. PMID: 29036787
    7. In advanced lung adenocarcinoma, infiltration of CCL18(+) tumor-associated macrophages (TAMs) was increased and higher expression of CCL18 by TAMs was associated with a favorable prognosis in lymph-node positive NSCLC PMID: 29970512
    8. This study study discovered a positive feedback loop between CTGF and CCL18 in hepatocellular carcinoma metastasis. PMID: 28837877
    9. All patients with NPC1 mutations had high ChT activity, high CCL18/PARC concentrations and/or Niemann-Pick disease type C suspicion index scores >/=70. PMID: 28222799
    10. findings suggest that these pulmonary markers could be useful to assess CAP severity and, especially YKL-40 and CCL18 by helping predict CAP caused by atypical pathogens PMID: 29324810
    11. PARC activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. PMID: 28234357
    12. Matrigel invasion assays revealed that tumor ECM-educated macrophages efficiently stimulated cancer cell invasion through a mechanism involving CCL18. PMID: 28209528
    13. Our results indicate that CCL18 acts in an autocrine manner via Akt activation to stimulate oral squamous cell carcinoma cell growth and invasion during disease progression PMID: 26919103
    14. Our data indicate that hypoxic inhibition of JMJD3 activity reduces demethylation of H3K27me3, nucleosome removal, and hence induction of the STAT6 target gene CCL18, while induction of other STAT6-inducible genes such as SPINT2 remained unaffected by JMJD3. PMID: 27737800
    15. There was no association between serial CCL18 concentrations with tumor response and overall survival. PMID: 28957436
    16. CCL-18 is a promising biomarker in COPD, as it is associated with frequency of exacerbations, particularly with severe COPD exacerbations requiring hospitalization, as well as with functional parameters and symptom scores. PMID: 28115842
    17. Data suggested that CCL18 upregulated Slug expression to promote epithelial-mesenchymal transition (EMT) and stem cell-like features by activating the mTOR pathway in oral cancer. PMID: 28574664
    18. An increased lung protein expression of PARC in chronic obstructive pulmonary disease patients PMID: 28545096
    19. CCL18 can increase the invasive ability of non-small cell lung cancer cells by binding to its receptor Nir1. PMID: 26756176
    20. Results demonstrate that high levels of CCL18 are present in ovarian cancer (OC) ascites and that CCL18 is an important component of ascites for the ascites-mediated migration of OC cells. Ascites and CCL18 stimulate the phosphorylation and expression of Pyk2, which is critical for mediated CCL18-induced migration. PMID: 27613122
    21. Data suggest that circulating CCL18 and abdominal subcutaneous white adipose tissue-secreted CCL18 correlates with insulin resistance and metabolic syndrome risk score; because CCL18 is macrophage-specific and associates with adipose immune gene expression, it may constitute a marker of adipose tissue inflammation (panniculitis). PMID: 27459538
    22. Cytomegalovirus replication in the allograft causes an intrapulmonary increase of CCL-18 and CCL-20 and a systemic rise of CCL-20 serum levels. Strong intrapulmonary CCL-18 responses are associated with symptomatic HCMV disease, proposing that CCL-18 BALF levels could serve as a marker. PMID: 26910332
    23. Study determined that CCL18 expression was up-regulated in ovarian carcinoma suggesting that CCL18 may play an important role in the pathogenicity of epithelial ovarian cancer through the induction of regulators and the activation of signaling pathways including mTORC2 signaling pathways. PMID: 26457987
    24. CCL18 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
    25. release of CCL18 with greater non-small cell lung cancer tumor size is most likely due to the accompanied growth of leukocyte infiltrate PMID: 27630310
    26. this study shows that CCL18 has a correlation with cardiac function in patients with acute anterior myocardial infarction PMID: 27350631
    27. our findings establish a signaling role for CCL18 in gastric cancer cells and identify that the CCL18/ERK1/2/NF-kappaB signaling pathway is essential for tumor invasiveness in gastric cancer cells. PMID: 26242263
    28. CCL18 enhances hepatocellular carcinoma (HCC) cell migration, invasion, and epithelial-mesenchymal transition (EMT) through the expression of PITPNM3 and the activation of the NF-kappaB signaling pathway. PMID: 26449829
    29. our findings suggest that CCL18 released from tumor-associated macrophages promotes angiogenesis and tumor progression in breast cancer. PMID: 26416449
    30. Findings suggest that down-regulation of miR98 and miR27b promotes CCL18-mediated invasion and migration of breast cancer cells. PMID: 26244871
    31. CCL18 is significantly up-regulated in breast cancer vs benign tumors or normal breast. It increased with the size of tumors, the number of lymph node metastasis, and advancing tumor stage. PMID: 26294068
    32. A common CCL18 polymorphism together with intraventricular hemorrhage had an additive influence on cerebral palsy susceptibility. PMID: 26113374
    33. The CCL18 levels in serum and synovial fluid are correlated with the severity of osteoarthritis. PMID: 25794928
    34. Combined functions of CCL18 in mesenchymal and cancer cells might accelerate the progression of PDAC by promoting the epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells. PMID: 25502147
    35. Increased CCL18 levels characterize chronic Pseudomonas aeruginosa infection and pulmonary obstruction in patients with cystic fibrosis. PMID: 25142483
    36. upregulation of CCL18 may be involved in the malignant progression of prostate cancer. PMID: 25197632
    37. CCL-18 and IGFBP-6 were identified as new potential serum biomarkers for prostate cancer. PMID: 24747338
    38. CCL18 expression was positively correlated with malignancy in EC. PMID: 25275026
    39. Pyk2 and Src are important in CCL18-induced breast cancer metastasis PMID: 24142406
    40. CCL18 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
    41. CCL18 from tumor-associated macrophages induces cancer cell epithelial-mesenchymal transition, forming a positive feedback loop, in coculture systems and humanized mice. PMID: 24823638
    42. Further development of A1AT as a diagnostic biomarker for BCa is warranted. PMID: 24011266
    43. the Cys10-Cys34 disulfide bond is involved in the function of CCL18. PMID: 23742785
    44. genetic polymorphism is associated with lung function in Hutterites, who are a founder population of European descent in North America PMID: 23932459
    45. In patients with systemic sclerosis-related interstitial lung disease, CCL18 was a predictor of short-term decline in forced vital capacity. It was not a longterm prognostic indicator. PMID: 23588945
    46. Data indicate that PYK2 N-terminal domain interacting receptor 1 (Nir1) could induce epithelial-mesenchymal transition by stabilising Snail via the PI3K/Akt/GSK3beta/Snail signalling pathway through binding to CCL18. PMID: 24001613
    47. this review focuses on the potential role, in asthma and lung immunity, of CCL18 a chemokine both constitutively expressed at high levels in the lung and induced in inflammatory conditions PMID: 23786278
    48. Identification of human CCR8 as a CCL18 receptor. PMID: 23999500
    49. A high CCL18 level might be an independent biomarker for predicting better survival of patients with colorectal cancer. PMID: 23433718
    50. CCL18 may be an interesting therapeutic target for NSCLC PMID: 23349697

    顯示更多

    收起更多

  • 亞細胞定位:
    Secreted.
  • 蛋白家族:
    Intercrine beta (chemokine CC) family
  • 組織特異性:
    Expressed at high levels in lung, lymph nodes, placenta, bone marrow, dendritic cells present in germinal centers and T-cell areas of secondary lymphoid organs and macrophages derived from peripheral blood monocytes. Not expressed by peripheral blood mono
  • 數據庫鏈接:

    HGNC: 10616

    OMIM: 603757

    KEGG: hsa:6362

    STRING: 9606.ENSP00000004921

    UniGene: Hs.143961



主站蜘蛛池模板: 欧美最猛性xxxxx免费| 欧美网站免费观看在线| 久久精品中文騷妇女内射| 国内裸体无遮挡免费视频| 久久综合精品国产一区二区三区无码| 亚洲国产精品久久久久爰| 中国熟女仑乱hd| 久久久噜噜噜www成人网| 夜夜影院未满十八勿进| 少妇精品导航| 永久免费的av在线电影网 | 中文人妻av大区中文不卡| 国产亚洲精品a片久久久| 亚洲码欧美码一区二区三区| 岛国av无码免费无禁网站| 欧美一性一乱一交一视频| 亚洲综合无码无在线观看| 久久人人做人人爽人人av| 国产成人精品av| 亚洲 成人 无码 在线观看| 欧美精品亚洲精品日韩专区va| 337p日本大胆欧久久| 一区二区三区在线 | 日| 在线观看人成视频免费| 丰满人妻熟妇乱又伦精品视| 久久精品成人免费国产| 亚洲kkk4444在线观看| 精品无码专区亚洲| 国产老熟女伦老熟妇露脸| 蜜臀av午夜一区二区三区| 欧美乱强伦xxxxx高潮| 国产两女互慰高潮视频在线观看| 国产精品久久国产精品99 | 国产微拍精品一区二区| 人妻无码久久精品人妻| yy6080久久伦理一区二区| 美女视频黄的全免费视频网站 | 狠狠色噜噜狠狠狠狠97首创麻豆| 亚洲a成人无码网站在线| 亚洲午夜精品a片一区二区app| 国产又色又爽又黄又免费|